Androgenetic alopecia (AGA) is the most prevalent form of chronic hair loss, affecting both men and women and often leading to significant psychosocial distress. Platelet-rich plasma (PRP) has recently gained attention as a therapeutic option for AGA, though its effectiveness has been variably reported. This systematic review evaluated the efficacy and safety of PRP based on evidence from randomized controlled trials (RCTs) and prospective studies involving male, female, or mixed cohorts. A comprehensive literature search was conducted across MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, and Google Scholar up to June 2025. Thirteen studies involving a total of 743 participants were included in the qualitative synthesis, with ten eligible for meta-analysis. Among these, six studies focused on male patients, two on females, and five included both sexes. The pooled data revealed a statistically significant improvement in hair density and hair count in participants treated with PRP compared to control groups. Patient satisfaction scores were consistently higher with PRP, and adverse effects were minimal. These findings suggest that PRP is a promising, safe, and minimally invasive treatment option for AGA. However, standardization of PRP preparation and treatment protocols is necessary to enhance reproducibility and facilitate broader clinical adoption.
Sanad et al. (Mon,) studied this question.